The phosphoramidate-based PSMA inhibitors were shown to rapidly internalize into subcellular organelles of PSMA-positive (PSMA+) prostate tumor cells, presumably through the enzyme-inhibitor complex [73]. The gene discussed is FOLH1; the disease is prostate neoplasm.